News Release

Biotech Support Group Presents Stroma Liquid Biopsy Cancer Data at HUPO World Congress 2017

MONMOUTH JUNCTION, NJ, October 5, 2017 –Biotech Support Group described a panel of protein biomarkers dysregulated in cancer at the recent HUPO World Congress, that took place September 17-21 in Dublin, Ireland. This research shows that there are three common pathways which change in the bloodstream regardless of the primary tumor, stage, metastatic disease, or tumor burden. Five different cancers – lung, breast, pancreatic, lymph and ovary, were profiled along with normal/healthy individuals of approximate age and matched sex for comparison.

The presentation is entitled “Stroma Liquid Biopsy – Biomarkers of the Dysregulation of the Serum Proteome in Cancer. It can be downloaded at:
http://www.biotechsupportgroup.com/v/vspfiles/temp...

“After several years of optimizing our methods and aggregating our data, I am very pleased that we can report what we believe are significant discoveries for improving outcomes for cancer patients. Our selection of biomarkers offer key advantages as they are all highly observable, being of relative high abundance in the bloodstream. Furthermore, they are all highly differentiated – many severely, in the cancer population, and very stable in the normal/healthy population. Under the guidance of a physician, such dysregulated patterns may serve within the context of current ‘liquid biopsy’ platforms, forming an early indicator for cancer even before clinical evidence. These same patterns may be prognostic as well as offer individualized and precision therapy for a patient. Further refined algorithms for each of these purposes: early detection, prognosis and therapeutic options, can be made with additional investigations in the future. We are looking forward to partnering with organizations to continue to expand on these proprietary discoveries”, states Dr. Swapan Roy, Ph.D., President and Founder of Biotech Support Group. 

About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in heathcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients.

For more information, go to http://www.biotechsupportgroup.com

Contact:
Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com